China Nuclear Medicine Market Size & Outlook, 2026-2033
Global Market
Related Markets
China nuclear medicine market highlights
- The China nuclear medicine market generated a revenue of USD 954.0 million in 2025 and is expected to reach USD 1,880.0 million by 2033.
- The China market is expected to grow at a CAGR of 8% from 2026 to 2033.
- In terms of segment, diagnostics was the largest revenue generating product in 2025.
- Diagnostics is the most lucrative product segment registering the fastest growth during the forecast period.
Nuclear medicine market data book summary
| Market revenue in 2025 | USD 954.0 million |
| Market revenue in 2033 | USD 1,880.0 million |
| Growth rate | 8% (CAGR from 2026 to 2033) |
| Largest segment | Diagnostics |
| Fastest growing segment | Diagnostics |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Diagnostics, Therapeutics |
| Key market players worldwide | GE HealthCare Technologies Inc Common Stock, Jubilant Pharmova, Nordion, Bracco, Iren SpA, Abliva AB, Lantheus Holdings Inc, Eckert & Ziegler Bebig SA, Mallinckrodt PLC Ordinary Shares - New, Cardinal Health Inc |
Other key industry trends
- In terms of revenue, China accounted for 4.5% of the global nuclear medicine market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Asia Pacific, China nuclear medicine market is projected to lead the regional market in terms of revenue in 2033.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 1,880.0 million by 2033.
The demand for 99Mo/99mTc is increasing in China. There are currently two ongoing projects in the country that are focused on producing Mo-99 to meet the rising demand. Projects include the China Advanced Research Reactor (CARR), which started operations in 2010 & the testing of Mo-99 is expected to start by 2020 and Medical Isotope Production Reactor (MIPR), which is operated by the Nuclear Power Institute of China (NPIC).
More than 800 hospitals in China have nuclear medicine facilities. For instance, China Isotope & Radiation Corporation (CIRC), a subsidiary of China National Nuclear Corporation (CNNC), has exported seven different kinds of products, including design & installation for Cobalt-60 radiation processing facility, radioactive sources, 99Mo-99mTc generator, and 99mTc kits, to more than 50 countries.
Local companies entering into licensing agreements with foreign organizations for the production & development of radioisotopes is expected to boost market growth in China. For instance, in November 2019, ITM Isotopen Technologien München AG (ITM) & Chengdu Gaotong Isotope Co., Ltd. entered into a licensing agreement to produce and distribute ITM’s Germanium-68/Gallium-68 Generators and n.c.a Lu-177 (EndolucinBeta) in China.
No credit card required*
Publish Date: Jun 17, 2026
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Nuclear Medicine Market Scope
Nuclear Medicine Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| GE HealthCare Technologies Inc Common Stock | View profile | 51,000 | 500 West Monroe Street, Chicago, IL, United States, 60661 | www.gehealthcare.com |
| Cardinal Health Inc | View profile | 48,000 | 7000 Cardinal Place, Dublin, OH, United States, 43017 | www.cardinalhealth.com |
| Mallinckrodt PLC Ordinary Shares - New | View profile | 2,700 | College Business and Technology Park, Cruiserath, Blanchardstown, Dublin, Ireland, 15 | www.mallinckrodt.com |
| Eckert & Ziegler Bebig SA | View profile | 501-1000 | Seneffe, Hainaut, Belgium, Europe | www.ezag.com/home/ |
| Nordion | View profile | 251-500 | Kanata, Ontario, Canada, North America | nordion.com |
| Bracco | View profile | 1001-5000 | Milan, Lombardia, Italy, Europe | www.bracco.com |
| Lantheus Holdings Inc | View profile | 834 | 201 Burlington Road, South Building, Bedford, MA, United States, 01730 | www.lantheus.com |
| Jubilant Pharmova | View profile | 10001+ | Noida, Uttar Pradesh, India, Asia | www.jubilantpharmova.com |
| Iren SpA | View profile | 10,000 | Via Nubi di Magellano, 30, Reggio Emilia, Italy, 42123 | www.gruppoiren.it |
| Abliva AB | View profile | 6 | Scheeletorget 1, Medicon Village, Lund, Sweden, 223 81 | www.abliva.com |
China Nuclear Medicine Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Nuclear Medicine Market Outlook will help companies and investors design strategic landscapes.
Diagnostics was the largest segment with a revenue share of 88.39% in 2025.
Horizon Databook has segmented the China nuclear medicine market based on diagnostics, therapeutics covering the revenue growth of each sub-segment from 2021 to 2033.
The demand for 99Mo/99mTc is increasing in China. There are currently two ongoing projects in the country that are focused on producing Mo-99 to meet the rising demand. Projects include the China Advanced Research Reactor (CARR), which started operations in 2010 & the testing of Mo-99 is expected to start by 2020 and Medical Isotope Production Reactor (MIPR), which is operated by the Nuclear Power Institute of China (NPIC).
More than 800 hospitals in China have nuclear medicine facilities. For instance, China Isotope & Radiation Corporation (CIRC), a subsidiary of China National Nuclear Corporation (CNNC), has exported seven different kinds of products, including design & installation for Cobalt-60 radiation processing facility, radioactive sources, 99Mo-99mTc generator, and 99mTc kits, to more than 50 countries.
Local companies entering into licensing agreements with foreign organizations for the production & development of radioisotopes is expected to boost market growth in China. For instance, in November 2019, ITM Isotopen Technologien München AG (ITM) & Chengdu Gaotong Isotope Co., Ltd. entered into a licensing agreement to produce and distribute ITM’s Germanium-68/Gallium-68 Generators and n.c.a Lu-177 (EndolucinBeta) in China.
- China Nuclear Medicine Market Product Outlook (Revenue, USD Million , 2021-2033)
- Diagnostics
- Therapeutics
- China Nuclear Medicine Market Application Outlook (Revenue, USD Million , 2021-2033)
- Cardiology
- Neurology
- Oncology
- Thyroid
- Lymphoma
- Bone Metastasis
- Endocrine Tumor
- Pulmonary Scans
- Urology
- Other
- China Nuclear Medicine Market End Use Outlook (Revenue, USD Million , 2021-2033)
- Hospitals
- Diagnostic Centers
- Others
Reasons to subscribe to Nuclear Medicine Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Nuclear Medicine Market Outlook databook
- Our clientele includes a mix of Nuclear Medicine Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China Nuclear Medicine Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into China Nuclear Medicine Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
China Nuclear Medicine Market, 2021-2033 (US$M)
China nuclear medicine market statistics, by product, 2021-2033 (US$M)
